Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients […]
In order to face growing market demand for quality probiotic food supplements, Lallemand Health Solutions is investing in a brand new bacterial production plant in Mirabel, Canada. Using state-of-the-art equipment and production process, the new […]
Danone North America announces it is awarding two graduate students $25,000 each for the 7th year in a row. As the name indicates, the grant is designed for graduate students to study the role of […]
MaaT Pharma announced today the results from its ODYSSEE (NCT02928523) Phase 1b/2a clinical trial demonstrating that the Company’s proprietary MaaT Microbiome Restoration Biotherapeutic (MMRB) therapeutic is able to restore a functional microbiome in acute myeloid […]
Together with colleagues from Sweden and Luxembourg, scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have observed that, during a natural vaginal birth, specific bacteria from the mother’s gut […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced the initiation of a Phase 1 clinical study in healthy volunteers of […]
Upon analyzing the accumulated evidence that microbes inhabit or visit the brain and likely trigger Alzheimer’s disease, Leslie Norins, MD, PhD, concluded, “The suspects have been reliably placed at the crime scene.” Dr. Norins is CEO […]
The successful introduction of the 2018 Pharmabiotics Young Investigator Awards set the stage for its development as one of the most important and prestigious awards for young microbiome researchers. Co-initiated by the Pharmabiotic Research Institute […]
Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 […]
Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it […]
Trace Genomics®, a San Francisco Bay area startup developing revolutionary, AI-enabled diagnostic tools for farmers to increase yields and reduce costs, has closed a $13 million Series A round. Trace Genomics has launched the first […]